ClinicalTrials.gg
CompletedNCT01378416Updated Jul 12, 2011Results posted

Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

A Phase 1 interventional study of Decitabine (Dacogen) in Leukemia, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-07-12.

Primary conditionLeukemia, Myeloid, AcuteRegistry: LeukemiaReclassifiedWhy we changed it
Registry
Leukemia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Myeloid, Acute
Why
  1. The study's title name Leukemia, Myeloid, Acute, a narrower term within Leukemia.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eisai Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 121 studies testing decitabine in Leukemia, Myeloid, Acute — 20 open to participants now, 33 under way, 2 of them phase 3. Decitabine · Leukemia, Myeloid, Acute.

Enrollment
91st of 120
16 · median 32
Started
2005
with 3 others
Phase 1
37 of 121
6 open now
Registered
14th of 121
by date
Lead sponsor
4 of 121
Eisai Inc.

Among the 121 studies testing decitabine in Leukemia, Myeloid, Acute, this one is the 91st largest by enrollment of the 120 interventional ones that give a count, is one of 4 that started in 2005, is one of 37 in phase 1, and was the 14th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

20 of the 121 studies testing decitabine in Leukemia, Myeloid, Acute are open now, in 5 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About decitabine

Decitabine: first FDA approval 2006 (DACOGEN), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies testing decitabine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The purpose of this study is to determine the pharmacokinetics (PK) of decitabine administered to patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).

03

Conditions studied

  • Leukemia

Browse trials for

Keywords

  • Acute myelogenous leukemia
  • myelodysplastic Syndrome
  • cancer
04

In context

Leukemia, Myeloid, Acute Reclassified

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

This study's enrollment of 16 is below the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.

Browse Leukemia, Myeloid, Acute studies →

Lead sponsor

Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.

Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.

Compared within Leukemia, Myeloid, Acute, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each patient had to meet the following criteria to be eligible for the study:

  1. Patients with MDS (de novo or secondary) must have been 60 years or older and have had disease fitting any of the recognized French-American-British classifications OR chronic myelomonocytic leukemia (with white blood cell [WBC] \<12,000/μL) AND have had an International Prognostic Scoring System score of ≥1.5 as determined by complete blood count, bone marrow assessment and bone marrow cytogenetics within 30 days of study entry.
  2. Patients with AML (≥30% bone marrow blasts) must have been age 18 years or older and had previously received standard induction chemotherapy and/or had failed approved therapies.
  3. Must have had (ECOG) performance status of 0 to 2.
  4. Must have signed an Institutional Review Board (IRB)-approved form, indicating his/her awareness of the nature of this study and its potential hazards prior to initiation of any study-specific procedures or treatment.
  5. Must have had adequate renal and hepatic function (creatinine ≤2.0 mg/dL, total \<2.0 mg/dL, (AST) and alanine aminotransferase (ALT) \<3.0 X institutional ).
  6. Must have had of at least 12 weeks.
  7. Must have recovered from all toxic effects of all prior therapy before entry into this study.

Exclusion criteria

Exclusion Criteria:

  1. Patients with MDS must not have been candidates for high-dose chemotherapy, bone marrow or stem cell transplant.
  2. Must not have had acute promyelocytic leukemia (M3 classification).
  3. Must not have received therapy for 30 days prior to study entry.
  4. Must not have had central nervous system (CNS) leukemia.
  5. Must not have received systemic , interferon, interleukins or other hormonal therapy within 30 days prior to study entry. Use of corticosteroids (topical and inhaled corticosteroids) was permitted and prophylactic steroids may have been used to treat or prevent transfusion reactions.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    1

    Drug: Decitabine (Dacogen)

Interventions

  • Intravenous injection; total dose-per-cycle was 135 mg/m\^2 of decitabine.

    Also known as: Dacogen

07

What researchers measure

Primary outcomes

  1. Average Total Body Clearance (Calculated From Rate and Concentration)

    3-hour IV infusion, every 8 hours for three consecutive days. Average Total Body Clearance was measured post first dose (Day 1), fourth dose (Day 2), and seventh dose (Day 3).

    Time frame: Day 1, Day 2, Day 3

  2. Cmax (Maximum Plasma Concentration)

    3-hour IV infusion, every 8 hours for three consecutive days. Cmax was measured post first dose (Day 1), fourth dose (Day 2), and seventh dose (Day 3).

    Time frame: Day 1, Day 2, Day 3

  3. Tmax (Time at Which Cmax First Observed)

    3-hour IV infusion, every 8 hours for three consecutive days. Tmax was measured post first dose (Day 1), fourth dose (Day 2), and seventh dose (Day 3).

    Time frame: Day 1, Day 2, Day 3

  4. AUC (0-∞) - Area Under the Plasma Concentration-time Curve Extrapolated to Infinity

    3-hour IV infusion, every 8 hours for three consecutive days. AUC (0-∞) was measured post first dose (Day 1), fourth dose (Day 2), and seventh dose (Day 3).

    Time frame: Day 1, Day 2, day 3

Secondary outcomes

  1. Safety: The Most Frequently Reported Adverse Events (Regardless of Causality)

    Summary of All Adverse Events (AEs) by Maximum Grade Occurring in \>= 10% Patients

    Time frame: 6 weeks

08

Results

Posted Jun 22, 2011

Participant flow

Participant flow — Overall Study
MilestoneDecitabine
Started16
Completed16
Not completed0

Outcome measures

SecondarySafety: The Most Frequently Reported Adverse Events (Regardless of Causality)

Summary of All Adverse Events (AEs) by Maximum Grade Occurring in \>= 10% Patients

Time frame:
6 weeks
Reported as:
Number · Participants
Safety: The Most Frequently Reported Adverse Events (Regardless of Causality)
ParticipantsDecitabine
Blood & Lymphatic System Disorders4
Cardiac Disorders2
Eye Disorders2
Gastrointestinal Disorders11
General Disorders & Administration Site Conditions14
Infections and Infestations7
Investigations - Weight decreased2
Metabolism and Nutrition5
Musculoskeletal and Connective Tissue Disorders6
Nervous System Disorders8
Psychiatric Disorders5
Respiratory, Thoracic and Mediastinal Disorders13
Skin and Subcutaneous Tissue Disorders9
PrimaryAverage Total Body Clearance (Calculated From Rate and Concentration)

3-hour IV infusion, every 8 hours for three consecutive days. Average Total Body Clearance was measured post first dose (Day 1), fourth dose (Day 2), and seventh dose (Day 3).

Time frame:
Day 1, Day 2, Day 3
Reported as:
Number · L/hr/m^2
Average Total Body Clearance (Calculated From Rate and Concentration)
L/hr/m^2Decitabine
Average Total Body Clearance (Calculated From Rate and Concentration)129 ± 48.6
PrimaryCmax (Maximum Plasma Concentration)

3-hour IV infusion, every 8 hours for three consecutive days. Cmax was measured post first dose (Day 1), fourth dose (Day 2), and seventh dose (Day 3).

Time frame:
Day 1, Day 2, Day 3
Reported as:
Mean · ng/mL
Cmax (Maximum Plasma Concentration)
ng/mLDecitabine
Day 173.8 ± 48.6
Day 264.8 ± 40.2
Day 377.0 ± 62.5
PrimaryTmax (Time at Which Cmax First Observed)

3-hour IV infusion, every 8 hours for three consecutive days. Tmax was measured post first dose (Day 1), fourth dose (Day 2), and seventh dose (Day 3).

Time frame:
Day 1, Day 2, Day 3
Reported as:
Mean · hours
Tmax (Time at Which Cmax First Observed)
hoursDecitabine
Day 12.49 ± 0.70
Day 22.53 ± 0.69
Day 32.29 ± 0.63
PrimaryAUC (0-∞) - Area Under the Plasma Concentration-time Curve Extrapolated to Infinity

3-hour IV infusion, every 8 hours for three consecutive days. AUC (0-∞) was measured post first dose (Day 1), fourth dose (Day 2), and seventh dose (Day 3).

Time frame:
Day 1, Day 2, day 3
Reported as:
Mean · ng∙hr/mL
AUC (0-∞) - Area Under the Plasma Concentration-time Curve Extrapolated to Infinity
ng∙hr/mLDecitabine
Day 1163 ± 101
Day 2152 ± 90.5
Day 3158 ± 101

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Decitabine—9/16 (56.3%)16/16 (100%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventDecitabine
Febrile NeutropeniaBlood and lymphatic system disorders3/16
ChillsGeneral disorders2/16
PneumoniaInfections and infestations2/16
SepsisInfections and infestations2/16
Disease ProgressionGeneral disorders1/16
PyrexiaGeneral disorders1/16
BacteraemiaInfections and infestations1/16
CellulitisInfections and infestations1/16
DiverticulitisInfections and infestations1/16
Acute Myeloid Leukemia RecurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/16
Most frequent other events
Showing 10 of 80
Most frequent other events
EventDecitabine
NauseaGastrointestinal disorders7/16
FatigueGeneral disorders6/16
CoughRespiratory, thoracic and mediastinal disorders6/16
DyspnoeaRespiratory, thoracic and mediastinal disorders6/16
ConstipationGastrointestinal disorders5/16
ChillsGeneral disorders4/16
PyrexiaGeneral disorders4/16
DizzinessNervous system disorders4/16
AnxietyPsychiatric disorders4/16
PneumoniaInfections and infestations3/16

Baseline characteristics

Age Continuous
Age Continuous(years)Decitabine
Mean68.2 ± 11.12
Sex: Female, Male
Sex: Female, Male(Participants)Decitabine
Female4
Male12
Region of Enrollment
Region of Enrollment(participants)Decitabine
United States16
09

Study locations

1 site
  • Washington University School of Medicine
    St. Louis, Missouri 63110, United States
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005, a primary completion of Jan 2006 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 5 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2008
First posted
Jun 22, 2011
Start
Apr 2005
Primary completionActual
Jan 2006
CompletionActual
Jun 2007
Results first posted
Jun 22, 2011
Last update
Jul 12, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01378416
Lead sponsor
Eisai Inc.
First posted
Jun 22, 2011
Start date
Apr 2005
Primary completion
Jan 2006
Completion
Jun 2007
Results posted
Jun 22, 2011
Last update
Jul 12, 2011

Study contacts

Gerard Kennealey, MD
study director · Eisai Medical Research (formerly MGI Pharma Inc.)
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Decitabine

Start the discussion